Fexaramine Inhibits Receptor Activator of Nuclear Factor-κB Ligand-induced Osteoclast Formation via Nuclear Factor of Activated T Cells Signaling Pathways
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Osteoclasts are bone resorbing cells and are responsible for bone erosion in diseases as diverse as osteoporosis, periodontitis, and rheumatoid arthritis. Fexaramine has been developed as an agonist for the farnesoid X receptor (FXR). This study investigated the effects of fexaramine on receptor activator of nuclear factor (NF)-κB ligand (RANKL)-induced osteoclast formation and signaling pathways. Methods: Osteoclasts were formed by culturing mouse bone marrow-derived macrophages (BMMs) with macrophage colony-stimulating factor (M-CSF) and RANKL. Bone resorption assays were performed using dentine slices. The mRNA expression level was analyzed by real-time polymerase chain reaction. Western blotting assays were conducted to detect the expression or activation level of proteins. Lipopolysaccharide-induced osteoclast formation was performed using a mouse calvarial model. Results: Fexaramine inhibited RANKL-induced osteoclast formation, without cytotoxicity. Furthermore, fexaramine diminished the RANKL-stimulated bone resorption. Mechanistically, fexaramine blocked the RANKL-triggered p38, extracellular signal-regulated kinase, and glycogen synthase kinase 3β phosphorylation, resulting in suppressed expression of c-Fos and NF of activated T cells (NFATc1). Consistent with the in vitro anti-osteoclastogenic effect, fexaramine suppressed lipopolysaccharide-induced osteoclast formation in the calvarial model. Conclusions: The present data suggest that fexaramine has an inhibitory effect on osteoclast differentiation and function, via downregulation of NFATc1 signaling pathways. Thus, fexaramine could be useful for the treatment of bone diseases associated with excessive bone resorption.
Abstract
Background: Osteoclasts are bone resorbing cells and are responsible for bone erosion in diseases as diverse as osteoporosis, periodontitis, and rheumatoid arthritis. Fexaramine has been developed as an agonist for the farnesoid X receptor (FXR). This study investigated the effects of fexaramine on receptor activator of nuclear factor (NF)-κB ligand (RANKL)-induced osteoclast formation and signaling pathways. Methods: Osteoclasts were formed by culturing mouse bone marrow-derived macrophages (BMMs) with macrophage colony-stimulating factor (M-CSF) and RANKL. Bone resorption assays were performed using dentine slices. The mRNA expression level was analyzed by real-time polymerase chain reaction. Western blotting assays were conducted to detect the expression or activation level of proteins. Lipopolysaccharide-induced osteoclast formation was performed using a mouse calvarial model. Results: Fexaramine inhibited RANKL-induced osteoclast formation, without cytotoxicity. Furthermore, fexaramine diminished the RANKL-stimulated bone resorption. Mechanistically, fexaramine blocked the RANKL-triggered p38, extracellular signal-regulated kinase, and glycogen synthase kinase 3β phosphorylation, resulting in suppressed expression of c-Fos and NF of activated T cells (NFATc1). Consistent with the in vitro anti-osteoclastogenic effect, fexaramine suppressed lipopolysaccharide-induced osteoclast formation in the calvarial model. Conclusions: The present data suggest that fexaramine has an inhibitory effect on osteoclast differentiation and function, via downregulation of NFATc1 signaling pathways. Thus, fexaramine could be useful for the treatment of bone diseases associated with excessive bone resorption.
참고문헌 (21)
- Zaidi M, "Skeletal remodeling in health and disease", Nat Med, 13, pp.791~801 (2007)
- Rodan GA, "Therapeutic approaches to bone diseases", Science, 289, pp.1508~1514 (2000)
- Suda T, "Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families", Endocr Rev, 20, pp.345~357 (1999)
- Boyle WJ, "Osteoclast differentiation and activation", Nature, 423, pp.337~342 (2003)
- Wong BR, "TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells", J Biol Chem, 272, pp.25190~25194 (1997)
- Theill LE, "RANK-L and RANK: T cells, bone loss, and mammalian evolution", Annu Rev Immunol, 20, pp.795~823 (2002)
- Lee ZH, "Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts", Biochem Biophys Res Commun, 305, pp.211~214 (2003)
- Jang HD, "Inactivation of glycogen synthase kinase-3beta is required for osteoclast differentiation", J Biol Chem, 286, pp.39043~39050 (2011)
- Matsuo K, "Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos", J Biol Chem, 279, pp.26475~26480 (2004)
- Wagner EF, "Fos", AP-1 proteins in bone and the immune system, 2005, pp.208, 126~140
- Asagiri M, "Autoamplification of NFATc1 expression determines its essential role in bone homeostasis", J Exp Med, 202, pp.1261~1269 (2005)
- Takayanagi H, "Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts", Dev Cell, 3, pp.889~901 (2002)
- Downes M, "A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR", Mol Cell, 11, pp.1079~1092 (2003)
- Wang YD, "FXR: a metabolic regulator and cell protector", Cell Res, 18, pp.1087~1095 (2008)
- Li T, "Bile acids as metabolic regulators", Curr Opin Gastroenterol, 31, pp.159~165 (2015)
- Cho SW, "Positive regulation of osteogenesis by bile acid through FXR", J Bone Miner Res, 28, pp.2109~2121 (2013)
- Ha H, "Alpha-Lipoic acid inhibits inflammatory bone resorption by suppressing prostaglandin E2 synthesis", J Immunol, 176, pp.111~117 (2006)
- Id Boufker H, "Role of farnesoid X receptor (FXR) in the process of differentiation of bone marrow stromal cells into osteoblasts", Bone, 49, pp.1219~1231 (2011)
- 김현주, "Deficiency of Lipocalin-2 Promotes Proliferation and Differentiation of Osteoclast Precursors via Regulation of c-Fms Expression and Nuclear Factorkappa B Activation", 대한골대사학회지, 23(1), pp.8~15 (2016), 대한골대사학회[DOI]
- 임희숙, "Relationship between Serum Inflammatory Marker and Bone Mineral Density in Healthy Adults", 대한골대사학회지, 23(1), pp.27~33 (2016), 대한골대사학회[DOI]
- Gennari L, "Treatment needs and current options for postmenopausal osteoporosis", Expert Opin Pharmacother, 17, pp.1141~1152 (2016)